In the last 10 years, the wide application of PDX (Patient-Derived Xenograft) has advanced preclinical evaluations and can forecast the clinical efficacy of tumor drugs. The pharmacodynamic effect of large-scale PDX models on anti-cancer drugs reflects the clinical application result in the patient populations. Therefore, researching the preclinical pharmacodynamic effects of new anti-cancer drugs by using PDX models is helpful for the deeper evaluation and potential clinical applications of new drugs.
1. The severely immuno-deficient B-NDG mice are more suitable than other immuno-deficient mice for PDX model establishment
2. The tumor model retains the high heterogeneity of tumor tissue, and partial medium compositions of tumor microenvironment are preserved
3. It overcomes the high homology problem of traditional models using tumor cell line cells, and more closely resembles the patient's tumor tissue
1. The PDX model library can provide a more in-depth assessment and potential preclinical applications of new drugs
2. It can be used in the preclinical evaluation and forecast clinical efficacy of tumor drugs
3.It is suitable to study the mechanism of tumorigenesis
PDX model successfully built on the B-NDG mouse (example)
PDX Tumor model & pharmacological efficacy test based on B-NDG mice
Fig 1.Different treatments show varying efficacies on our PDX model from the same patient cancer tissue.
Preclinical animal test samples can be collected from PDX models that are given different drug combinations to determine appropriate clinical therapies.